Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial.

United European gastroenterology journal·2026

Same author

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial.

Gut·2026

Same author

Waiting for cholecystectomy: determinants of prioritization for delayed cholecystectomy in a universal public healthcare system-post hoc analysis of RELAPSTONE cohort (WAIT-CHOL study).

BJS open·2026

Same author

Validation of Predictive Equations for Estimating Lean Soft Tissue and Fat-Free Mass in Class II-V Obesity: A Multicenter Observational Study with Implications for Bariatric Surgery Monitoring.

Journal of obesity & metabolic syndrome·2026

Same author

Editorial: Advancing gastrointestinal disease diagnosis with interpretable AI and edge computing for enhanced patient care.

Frontiers in medicine·2026

Same author

Higher Doses of Bismuth and Antibiotics Do Not Improve Helicobacter pylori Treatment Effectiveness: Results From the European Registry on Helicobacter pylori Management.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 7, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

Peptic ulcer disease.

Angel Lanas¹, Francis K L Chan²

¹Service of Digestive Diseases, University Clinic Hospital Lozano Blesa, University of Zaragoza, IIS Aragón, CIBEREHD, Zaragoza, Spain.

Lancet (London, England)

|March 1, 2017

Summary

This summary is machine-generated.

Peptic ulcer disease is less common but harder to treat due to antimicrobial resistance and complex therapies. New challenges arise from ulcers not linked to H. pylori or NSAIDs, requiring updated management strategies.

More Related Videos

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Related Experiment Videos

Last Updated: Mar 7, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance

Published on: March 7, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

Area of Science:

Gastroenterology
Internal Medicine
Pharmacology

Background:

Peptic ulcer disease (PUD) prevalence has decreased due to reduced Helicobacter pylori infection rates and increased use of proton pump inhibitors.
However, PUD management is increasingly complex, driven by rising antimicrobial resistance and widespread use of anti-thrombotic therapies in aging populations.
A growing number of ulcers unrelated to H. pylori or NSAIDs present unique diagnostic and therapeutic challenges.

Purpose of the Study:

To provide a comprehensive overview of current knowledge and recent advancements in peptic ulcer disease.
To discuss updated guidelines for H. pylori infection management and treatment of PUD complications.
To highlight unmet needs in the diagnosis and management of complex peptic ulcer cases.

Main Methods:

Review of recent literature on peptic ulcer pathogenesis and epidemiology.
Analysis of current clinical guidelines for H. pylori eradication and PUD management.
Discussion of therapeutic strategies for PUD associated with anti-thrombotic agents and NSAIDs.
Identification of knowledge gaps and future research directions.

Main Results:

Declining prevalence of H. pylori-associated PUD.
Increasing challenges in PUD management due to antimicrobial resistance and anti-thrombotic drug use.
Emergence of non-H. pylori, non-NSAID ulcers as a significant clinical issue.
Need for updated therapeutic approaches and further research.

Conclusions:

Peptic ulcer disease management requires adaptation to evolving epidemiological trends and therapeutic challenges.
Addressing antimicrobial resistance and optimizing treatment in patients on anti-thrombotic therapy are critical.
Further research is needed to understand and manage complex peptic ulcers effectively.